Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- eritema ou ulceração da mucosa oral
- dor oral
Outros fatores diagnósticos
- comprometimento alimentar
- diarreia
- febre
Fatores de risco
- esquemas de quimioterapia intensiva
- radioterapia na cavidade oral
- quimiorradiação
- polimorfismos genéticos em enzimas metabólicas do medicamento
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- diagnóstico clínico
Investigações a serem consideradas
- hemograma completo e diferencial
- hemoculturas
- esfregaço superficial da lesão para microscopia
- cultura fúngica
- cultura viral ou reação em cadeia da polimerase
Algoritmo de tratamento
pacientes submetidos a transplante de células-tronco hematopoéticas: medidas preventivas
pacientes que recebem fluoruracila em bolus: medidas preventivas
pacientes que recebem radioterapia na cavidade oral: medidas preventivas
mucosite oral estabelecida
Colaboradores
Autores
Rajesh V. Lalla, DDS, PhD, DABOM
Associate Professor
Associate Dean for Research
Section of Oral Medicine
University of Connecticut School of Dental Medicine
Farmington
CT
Declarações
RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics and Novartis.
Ourania Nicolatou-Galitis, DDS, MSc, DrDent
Professor
Hospital Dentistry
National & Kapodistrian University of Athens
Athens
Greece
Declarações
ONG has received fees from Angelini pharma to author a review article on oral mucositis. ONG is an author of several references cited in this topic.
Nikolaos Tsoukalas, MD, MSc, PhD
Medical Oncologist
Associate Director
Department of Oncology
401 General Military Hospital
Athens
Greece
Declarações
NT declares that he has no competing interests.
Agradecimentos
Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.
Declarações
EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.
Revisores
Michael Brennan, DDS, MHS
Associate Chairman and Oral Medicine Residency Director
Department of Oral Medicine
Carolinas Medical Center
Charlotte
NC
Declarações
MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.
Maria Michelagnoli, MB ChB, MD, FRCPCH
Consultant Pediatric and Adolescent Oncologist
University College London Hospitals
London
UK
Declarações
MM declares that she has no competing interests.
Diagnósticos diferenciais
- Candidíase oral
- Infecção pelo vírus do herpes simples
- Doença do enxerto contra o hospedeiro
Mais Diagnósticos diferenciaisDiretrizes
- Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Mais Diretrizes
Log in or subscribe to access all of BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal